|
|
|
Volumn 39, Issue 5, 2014, Pages
|
|
Pharmaceutical approval update
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADRENALIN;
ANTIHISTAMINIC AGENT;
ANTIPYRETIC AGENT;
COMPLEMENT COMPONENT C1S INHIBITOR;
ECULIZUMAB;
ELOSULFASE ALFA;
HYALURONIC ACID;
IDURONATE 2 SULFATASE;
LEVODOPA;
NEUROLEPTIC AGENT;
NORADRENALIN;
THREO 3, 4 DIHYDROXYPHENYLSERINE;
THREO 3,4 DIHYDROXYPHENYLSERINE;
UNCLASSIFIED DRUG;
AGE;
ANAPHYLAXIS;
ANGIONEUROTIC EDEMA;
CLINICAL TRIAL (TOPIC);
CONFUSION;
COUGHING;
DRUG APPROVAL;
DRUG COST;
DRUG DOSE REDUCTION;
DRUG EFFICACY;
DRUG SAFETY;
DRUG WITHDRAWAL;
DYSPNEA;
GASTROINTESTINAL SYMPTOM;
HEART OUTPUT;
HEART RATE;
HOT FLUSH;
HUMAN;
HUNTER SYNDROME;
HYPERPYREXIA;
HYPERTENSION;
HYPOTENSION;
KIDNEY CLEARANCE;
KIDNEY PERFUSION;
KNEE OSTEOARTHRITIS;
KNEE PAIN;
LUNG VASCULAR RESISTANCE;
MORQUIO SYNDROME;
NEUROGENIC ORTHOSTATIC HYPOTENSION;
NEUROLEPTIC MALIGNANT SYNDROME;
NOTE;
ORTHOSTATIC HYPOTENSION;
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA;
PIGMENT DISORDER;
PREGNANCY;
RASH;
RISK;
SINGLE DRUG DOSE;
SLEEP DISORDERED BREATHING;
SPINAL CORD COMPRESSION;
SUPINE HYPERTENSION;
TACHYCARDIA;
THORAX PAIN;
THROAT TIGHTNESS;
URTICARIA;
|
|
EID: 84901432994
PISSN: 10521372
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (8)
|
|
References (0)
|
